Cash Flow Statement (Annual)

HALO / Halozyme Therapeutics, Inc. Short Interest

HALO / Halozyme Therapeutics, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss -58,361 -53,242 -19,770 -53,552 -83,479 -68,375 -32,231 -103,023 62,971
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Share Based Compensation 4,526 4,866 5,570 8,349 9,538 15,274 20,838 25,585 30,670
    Depreciation Depletion And Amortization 1,444 1,508 1,096 1,079 1,227 1,762 1,677 2,410 2,200
    Amortization Of Financing Costs - - 0 9 156 2,025 1,243 2,896 1,761
    Paid In Kind Interest - - - - - 0 879 13,184 0
    Accretion Amortization Of Discounts And Premiums Investments - - 0 0 -1,116 -1,457 -879 -552 303
    Gain Loss On Sale Of Property Plant Equipment -3 -14 2 -7 0 -233 -8 -8 -46
    Increase Decrease In Deferred Revenue 11,034 -2,389 -17,210 2,962 9,297 1,490 -1,411 701 22,759
    Recognition Of Deferred Revenue - - - - - 5,554 5,789 9,304 6,512
    Straight Line Rent - - - - - - 276 370 185
    Other Operating Activities Cash Flow Statement - - - - - - 0 0 -16
    Increase Decrease In Operating Capital
      Increase Decrease In Accounts Receivable -3,021 -1,916 -66 13,441 -6,606 52 23,261 -16,730 6,453
      Increase Decrease In Inventories 718 -966 374 2,103 3,499 236 3,083 5,134 -9,477
      Increase Decrease In Prepaid Deferred Expense And Other Assets -1,017 2,147 4,611 4,421 -1,959 265 15,774 -5,626 -2,035
      Increase Decrease In Accounts Payable And Accrued Liabilities -2,000 3,437 712 -3,263 7,889 -816 13,866 -244 15,629
      Net Cash Provided By Used In Operating Activities Continuing Operations - - - - - - -37,083 -50,383 134,053
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Available For Sale Securities - - 0 0 48,947 88,884 71,482 155,412 398,187
  Proceeds From Sale Of Available For Sale Securities - - 0 0 3,375 57,301 79,730 81,783 235,805
  Payments To Acquire Property Plant And Equipment 1,461 647 829 1,413 2,298 1,368 2,360 3,137 1,350
  Net Cash Provided By Used In Investing Activities Continuing Operations - - - - - - 5,888 -76,766 -163,732
Net Cash Provided By Used In Financing Activities
  Proceeds From Issuance Of Common Stock 38,174 59,965 0 81,477 0 107,713 0 0 134,874
  Proceeds From Debt Net Of Issuance Costs - 0 0 29,661 19,985 0 0 203,006 0
  Repayments Of Secured Debt - - - - - 0 0 54,250 15,995
  Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options - - - - 5,079 6,788 13,098 1,865 12,776
  Net Cash Provided By Used In Financing Activities Continuing Operations - - - - - - 13,098 150,621 131,655
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - -18,097 23,472 101,976
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - 169,240

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 40637H109